As Novartis Buys In to Gene Therapy, GSK Bows Out with Orchard Deal – Xconomy
Xconomy |
As Novartis Buys In to Gene Therapy, GSK Bows Out with Orchard Deal
Xconomy Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn't yet seen commercial success. In the same week, GlaxoSmithKline, which has one of the few gene therapies on the market but has struggled to sell it, is … GSK sells rare disease gene therapy portfolio – Financial Times GSK slims portfolio with sale of rare disease gene therapy drugs UK gene therapy firm Orchard plans stock offer after GSK deal |
